Tjebo F C Heeren1,2, Diána Kitka1, Daniela Florea1, Traci E Clemons3, Emily Y Chew4, Alan C Bird1, Daniel Pauleikhoff5, Peter Charbel Issa2,6, Frank G Holz2, Tunde Peto1,7. 1. NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom. 2. Department of Ophthalmology, University of Bonn, Bonn, Germany. 3. The Emmes Corporation, Rockville, Maryland. 4. National Eye Institute, Bethesda, Maryland. 5. Department of Ophthalmology, St Franziskus Hospital, Munster, Germany. 6. Oxford Eye Hospital, OUH NHS Foundation Trust and the Nuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, University of Oxford. 7. Centre for Public Health, Queen's University Belfast, Belfast, United Kingdom.
Abstract
PURPOSE: To compare ellipsoid zone (EZ) loss and functional loss in macular telangiectasia (MacTel) type 2 longitudinally. METHODS: Prospective natural history study. Ellipsoid zone loss was measured in en-face images created from spectral domain optical coherence tomography. Functional loss was assessed by best-corrected visual acuity and microperimetry, counting the number of test points with impaired function. RESULTS: A total of 56 eyes of 31 participants were followed for 4.5 ± 1.2 years. Ellipsoid zone loss was 18,600 ± 3,917.3 pixel at baseline (≈0.59 mm) and increased 2,627.8 ± 427.9 pixel (≈0.08 mm) per year. Best-corrected visual acuity decreased 2.2 ± 0.9 letters per year. Change in EZ loss correlated significantly with change in relative and absolute scotomas (r = 0.62; P-value < 0.0001 and r = 0.72; P-value < 0.0001), but not with loss of best-corrected visual acuity. Functional loss showed a similar frequency of progression as EZ loss, but a higher rate of "regression," likely due to higher variability of the measurement, assuming a progressive neurodegenerative disease. CONCLUSION: The results of the authors support EZ loss as surrogate measure for visual function in MacTel type 2. Being objective, EZ loss might be considered more suitable than microperimetry as primary end point in future interventional trials.
PURPOSE: To compare ellipsoid zone (EZ) loss and functional loss in macular telangiectasia (MacTel) type 2 longitudinally. METHODS: Prospective natural history study. Ellipsoid zone loss was measured in en-face images created from spectral domain optical coherence tomography. Functional loss was assessed by best-corrected visual acuity and microperimetry, counting the number of test points with impaired function. RESULTS: A total of 56 eyes of 31 participants were followed for 4.5 ± 1.2 years. Ellipsoid zone loss was 18,600 ± 3,917.3 pixel at baseline (≈0.59 mm) and increased 2,627.8 ± 427.9 pixel (≈0.08 mm) per year. Best-corrected visual acuity decreased 2.2 ± 0.9 letters per year. Change in EZ loss correlated significantly with change in relative and absolute scotomas (r = 0.62; P-value < 0.0001 and r = 0.72; P-value < 0.0001), but not with loss of best-corrected visual acuity. Functional loss showed a similar frequency of progression as EZ loss, but a higher rate of "regression," likely due to higher variability of the measurement, assuming a progressive neurodegenerative disease. CONCLUSION: The results of the authors support EZ loss as surrogate measure for visual function in MacTel type 2. Being objective, EZ loss might be considered more suitable than microperimetry as primary end point in future interventional trials.
Authors: Nathan Doble; Stacey S Choi; Johanan L Codona; Julian Christou; Jay M Enoch; David R Williams Journal: Opt Lett Date: 2011-01-01 Impact factor: 3.776
Authors: Drew Scoles; Yusufu N Sulai; Christopher S Langlo; Gerald A Fishman; Christine A Curcio; Joseph Carroll; Alfredo Dubra Journal: Invest Ophthalmol Vis Sci Date: 2014-06-06 Impact factor: 4.799
Authors: Ferenc B Sallo; Irene Leung; Traci E Clemons; Tunde Peto; Emily Y Chew; Daniel Pauleikhoff; Alan C Bird Journal: Retina Date: 2018-01 Impact factor: 4.256
Authors: Drew Scoles; John A Flatter; Robert F Cooper; Christopher S Langlo; Scott Robison; Maureen Neitz; David V Weinberg; Mark E Pennesi; Dennis P Han; Alfredo Dubra; Joseph Carroll Journal: Retina Date: 2016-01 Impact factor: 4.256
Authors: Frank G Holz; Almut Bindewald-Wittich; Monika Fleckenstein; Jens Dreyhaupt; Hendrik P N Scholl; Steffen Schmitz-Valckenberg Journal: Am J Ophthalmol Date: 2006-12-22 Impact factor: 5.258
Authors: Ferenc B Sallo; Tunde Peto; Catherine Egan; Ute E K Wolf-Schnurrbusch; Traci E Clemons; Mark C Gillies; Daniel Pauleikhoff; Gary S Rubin; Emily Y Chew; Alan C Bird Journal: Invest Ophthalmol Vis Sci Date: 2012-11-29 Impact factor: 4.799
Authors: Amir H Hariri; Hong Yang Zhang; Alexander Ho; Peter Francis; Richard G Weleber; David G Birch; Frederick L Ferris; SriniVas R Sadda Journal: JAMA Ophthalmol Date: 2016-06-01 Impact factor: 7.389
Authors: Peter Charbel Issa; Eric Troeger; Robert Finger; Frank G Holz; Robert Wilke; Hendrik P N Scholl Journal: PLoS One Date: 2010-09-22 Impact factor: 3.240
Authors: Daniel Pauleikhoff; Roberto Bonelli; Adam M Dubis; Frederic Gunnemann; Kai Rothaus; Peter Charbel Issa; Tjebo Fc Heeren; Tunde Peto; Traci E Clemons; Emily Y Chew; Alan C Bird; Ferenc B Sallo Journal: Acta Ophthalmol Date: 2019-04-09 Impact factor: 3.761
Authors: Marin L Gantner; Kevin Eade; Martina Wallace; Michal K Handzlik; Regis Fallon; Jennifer Trombley; Roberto Bonelli; Sarah Giles; Sarah Harkins-Perry; Tjebo F C Heeren; Lydia Sauer; Yoichiro Ideguchi; Michelle Baldini; Lea Scheppke; Michael I Dorrell; Maki Kitano; Barbara J Hart; Carolyn Cai; Takayuki Nagasaki; Mehmet G Badur; Mali Okada; Sasha M Woods; Catherine Egan; Mark Gillies; Robyn Guymer; Florian Eichler; Melanie Bahlo; Marcus Fruttiger; Rando Allikmets; Paul S Bernstein; Christian M Metallo; Martin Friedlander Journal: N Engl J Med Date: 2019-09-11 Impact factor: 91.245
Authors: Dibyendu Mukherjee; Eleonora M Lad; Ryan R Vann; Stephanie J Jaffe; Traci E Clemons; Martin Friedlander; Emily Y Chew; Glenn J Jaffe; Sina Farsiu Journal: Invest Ophthalmol Vis Sci Date: 2017-05-01 Impact factor: 4.799
Authors: Tyler A Berger; Matthew W Manry; Lucas B Lindsell; James M Osher; Daniel M Miller; Robert E Foster; Christopher D Riemann; Michael R Petersen; Robert A Sisk Journal: Clin Ophthalmol Date: 2021-03-15